A new clinical trial for HIV vaccinations will go into Phase 2 clinical trials this fall (2017). The HIV Vaccine (SAV001) developed at Western University will be tested in 600 HIV-negative people across North America sometime in Fall 2017. Once approved, the trial will determine the vaccine’s ability to produce anti-HIV antibodies in patients who are not infected with the virus. The results of the Phase 1 trial showed that the vaccine is both safe for use and effective in triggering an anti-HIV immune response in HIV-positive patients. The results also demonstrated that the vaccine was well tolerated with no serious adverse events.
Developed by Chil-Yong Kang and a research team at Western’s Schulich School of Medicine & Dentistry, the vaccine was tested in 33 HIV-positive volunteers. The next phase will involve 300 volunteers from the general population groups considered high risk for HIV infection. The SAV001 vaccine is unique in that it uses a killed whole HIV-1, much like the killed whole virus used in vaccines for polio, hepatitis A, rabies, and the flu. The killed HIV-1 is genetically engineered so that it is less dangerous and can be produced in large quantities. The vaccine is the world’s first preventative HIV vaccine using genetically modified killed whole-virus to receive approval by the FDA to proceed to human clinical trials.
Once Phase 2 has been successfully completed, Phase 3 will be conducted world-wide with 6,000 subjects and will be the true test to show if the vaccine is effective in protecting people against HIV infection. If successful, this will be a huge boon to the world as HIV/AIDS has killed more than 41 million people worldwide, and 35 million people currently live with the infection.
Have any other topics you want to hear about? Tell us about your ideas at email@example.com! And don’t forget to join our panel so you can share your ideas in our online communities!